These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12478080)

  • 1. Immunological changes during treatment interruptions: risk factors and clinical sequelae.
    Poulton MB; Sabin CA; Fisher M
    AIDS; 2003 Jan; 17(1):126-8. PubMed ID: 12478080
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study.
    Wit FW; Blanckenberg DH; Brinkman K; Prins JM; van der Ende ME; Schneider MM; Mulder JW; de Wolf F; Lange JM;
    AIDS; 2005 Feb; 19(3):345-8. PubMed ID: 15718848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
    Mussini C; Bedini A; Borghi V; Guaraldi G; Esposito R; Barchi E; Enilia R; Cozzi-Lepri A; Philips AN; Ortolani P; Bratt G; Eriksson LE; Sighinolfi L; Cossarizza A; d'Arminio Monforte A; De Luca A; Di Giambenedetto S; Antinori A;
    AIDS; 2005 Feb; 19(3):287-94. PubMed ID: 15718839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
    Collazos J; Asensi V; Cartón JA
    AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions.
    Hawley-Foss N; Mbisa G; Lum JJ; Pilon AA; Angel JB; Garber G; Badley AD
    Clin Infect Dis; 2001 Aug; 33(3):344-8. PubMed ID: 11438900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV treatment interruptions: a review.
    Newcomb-Fernandez J
    Res Initiat Treat Action; 2003; 9(2):5-13. PubMed ID: 14989199
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
    AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.
    Abbas UL; Mellors JW
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13377-8. PubMed ID: 12370421
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapies. Confronting the limits of success.
    Cohen J
    Science; 2002 Jun; 296(5577):2320-4. PubMed ID: 12089422
    [No Abstract]   [Full Text] [Related]  

  • 14. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
    AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
    Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM
    AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937
    [No Abstract]   [Full Text] [Related]  

  • 17. Trying to make sense of treatment interruptions.
    Lewis D; Sutton RE
    Res Initiat Treat Action; 2003; 9(2):14-5. PubMed ID: 14989200
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
    AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection.
    Chiappini E; Galli L; Tovo PA; Gabiano C; Gattinara GC; Guarino A; Badolato R; Giaquinto C; Lisi C; de Martino M;
    AIDS; 2006 Jan; 20(2):207-15. PubMed ID: 16511413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients.
    Landman R; Damond F; Gerbe J; Brun-Vezinet F; Yeni P; Matheron S
    AIDS; 2009 Jan; 23(3):426-8. PubMed ID: 19114866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.